Status:

COMPLETED

Safety and Immunogenicity of GSK's Tdap Vaccine (Boostrix) in Adults Aged 19 to 64 Years

Lead Sponsor:

GlaxoSmithKline

Conditions:

Acellular Pertussis

Diphtheria

Eligibility:

All Genders

19-64 years

Phase:

PHASE3

Brief Summary

GSK Biologicals' dTpa vaccine has recently been approved by the US Food and Drug Administration (FDA) for booster vaccination of adolescents aged 10 to 18 years. The ACIP has recently issued provision...

Eligibility Criteria

Inclusion

  • A healthy male or female, 19 to 64 years of age (not having reached the 65th birthday) at the time of study vaccination.

Exclusion

  • Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding administration of study vaccine, or planned use during the active phase of the study.
  • Chronic administration of immunosuppressants or within six months prior to administration of study vaccine.
  • Planned administration/ administration of a vaccine not foreseen by the study protocol within 30 days of administration of study vaccine (with the exception of an influenza vaccine).
  • Administration of a diphtheria-tetanus (Td) booster within previous five years.
  • Administration of Tdap vaccine at any time prior to study entry. History of serious allergic reaction (e.g. anaphylaxis) following any other tetanus toxoid, diphtheria toxoid or pertussis-containing vaccine or any component of the study vaccines.

Key Trial Info

Start Date :

July 13 2006

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

March 7 2007

Estimated Enrollment :

2337 Patients enrolled

Trial Details

Trial ID

NCT00346073

Start Date

July 13 2006

End Date

March 7 2007

Last Update

August 7 2018

Active Locations (42)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 11 (42 locations)

1

GSK Investigational Site

Huntsville, Alabama, United States, 35802

2

GSK Investigational Site

Chandler, Arizona, United States, 85224

3

GSK Investigational Site

Mesa, Arizona, United States, 85203

4

GSK Investigational Site

Mesa, Arizona, United States, 85213